Celecoxib (Celebrex™) Receives FDA Approval as Adjunctive Treatment for FAP

The U.S. Food and Drug Administration (FDA) has approved Celecoxib (Celebrex) as an oral adjunct to usual care for patients with adenomatous polyposis (FAP). FAP is a rare hereditary disease that, left untreated, almost always leads to colorectal cancer. Celecoxib, indicated for the treatment of both osteoarthritis and adult rheumatoid arthritis, is the first pharmacologic agent to be indicated to reduce the number of adenomatous colorectal polyps in patients with familial FAP.